Southwest Oncology Group

西南肿瘤组

• 批准号: 7049441
• 负责人: LAURENCE HOWARD BAKER
• 金额: $ 25.52万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1980
• 资助国家: 美国
• 起止时间: 1980-01-01 至 2006-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7049441
• 关键词: antineoplastics; bleomycin; blood /lymphatic neoplasm; bone marrow transplantation; brain neoplasms; breast neoplasms; cancer information system; cancer prevention; cancer registry /resource; cis platinum compound; clinical research; clinical trial phase II; clinical trial phase III; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; doxorubicin; drug resistance; female reproductive system neoplasm; fludarabine; gastrointestinal neoplasms; head /neck neoplasm; hormone therapy; human subject; human therapy evaluation; ifosfamide; leukemia; lung neoplasms; lymphoma; meeting /conference /symposium; melanoma; multiple myeloma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; oncology nursing; paclitaxel; pancreas neoplasms; pathology; patient oriented research; prognosis; prostate neoplasms; quality of life; sarcoma; tamoxifen; tissue resource /registry; urinary tract neoplasms; women' s health

DESCRIPTION (provided by applicant): The University of Michigan has been participating as a fully funded member with Southwest Oncology Group (SWOG) since January 1, 1980. We view SWOG participation as an important component of a large cancer research effort at our institution. We remain committed to the concept that multi-institutional collaboration is essential to the advancement of cancer treatment. Our goals as a member institution in SWOG remain the same as in years past, namely to make significant scientific, administrative and patient data contributions to the Group's effort to study and improve cancer therapy. We continue to believe in the cooperative group process that involves the collection of patient data, adopting uniform toxicity and response criteria, and conducting purposeful clinical trials as well as introducing the concept of merging "spores" into the cooperative group mechanism. Cooperative groups have provided the only settings in which the sophisticated concepts of combined modality and adjuvant therapies could be properly investigated. The processes have also produced an improved understanding of the important relationships between prognostic factors, therapy and patient survival that could not have been gained otherwise. Our participation in SWOG is multidisciplinary with membership that included hematologists, medical oncologists, radiation oncologists, pathologists, surgeons and various surgical subspecialties (in particular urology oncology, orthopedics, breast, otolaryngology, gynecology and thoracic), nurses and clinical research associates all involved in group activities which has strengthened with the recruitment of senior leadership, as well as talented junior faculty to complement an already strong base of clinical and basic researchers. Our participation in SWOG during the last five years has been characterized by a high level of data management and protocol compliance, good level of administrative/scientific contributions and an average level of patient registration contributions, (1997 =41 pts, 1998= 33 pts, 1999= 47 pts, 2000= 33 pts, 2001 = 57 pts, 2002= 17 pts; total= 225 pts). We expect to increase patient accrual to approximately 50-100 pts per year with the increased commitment amongst SWOG investigators at the University of Michigan and CGOP affiliates.

描述（由申请人提供）：自 1980 年 1 月 1 日以来，密歇根大学一直作为西南肿瘤学小组 (SWOG) 的全额资助成员参与其中。我们认为 SWOG 的参与是我们机构大型癌症研究工作的重要组成部分。我们仍然致力于多机构合作对于推进癌症治疗至关重要的理念。作为 SWOG 成员机构，我们的目标与过去几年相同，即为该集团研究和改进癌症治疗的努力做出重大的科学、管理和患者数据贡献。我们仍然相信合作小组的过程，包括收集患者数据、采用统一的毒性和反应标准、进行有目的的临床试验以及将“孢子”合并的概念引入合作小组机制。合作团体提供了唯一可以适当研究联合治疗和辅助治疗的复杂概念的环境。这些过程还使人们更好地了解了预后因素、治疗和患者生存之间的重要关系，这是通过其他方式无法获得的。 我们对 SWOG 的参与是多学科的，成员包括血液学家、肿瘤内科医师、放射肿瘤学家、病理学家、外科医生和各种外科亚专业（特别是泌尿肿瘤科、骨科、乳腺科、耳鼻喉科、妇科和胸科）、护士和临床研究助理，所有这些人员都参与了 SWOG通过招募高级领导和有才华的初级教师来补充已经强大的临床和基础研究人员基础，小组活动得到了加强。我们在过去五年中参与 SWOG 的特点是高水平的数据管理和协议合规性、良好的行政/科学贡献水平以及平均水平的患者注册贡献（1997 年 = 41 分，1998 年 = 33 分， 1999年= 47分，2000年= 33分，2001年= 57分，2002年= 17分分；总计 = 225 分）。随着密歇根大学和 CGOP 附属机构的 SWOG 研究人员加大投入，我们预计每年将患者数量增加到约 50-100 分。